Dizhi Pharmaceuticals (688192.SH): Multiple latest research results in the field of lung cancer will be announced at the 2025 World Conference on Lung Cancer (WCLC).

Wisdom Financial News App: Deco Pharmaceuticals (688192.SH) announced that the company reported its independently developed new lung cancer targeted drug Shuwuzhe (generic name: Shuwotinib tablets) and highly selective JAK1 inhibitor Gaorui (generic name: Golixitinib capsules) in the field of non-small cell lung cancer (NSCLC) at the 2025 World Lung Cancer Conference (WCLC) from September 6th to 9th, 2025. Among them, the latest research results of the international multicenter registered clinical study of Shuwuzhe "Wukong 1B" (WU-KONG1B) were presented orally at the conference.